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a b s t r a c t
Objective: Evaluate SLE stable patients, without overt respiratory compromise, by means of 
6MWT.
Casuistic and methods: Forty-five stable SLE patients were enrolled. The ATS/ERS protocol for 
6MWT, was used and two parameters with cut-off points were chosen.
Results: Forty-two patients were women. The mean age was 39 ± 11.4 years; mean duration 
of disease, 121 ± 93.1 months; mean value of MRC, 2 ± 0; mean FVC, 85.9 ± 34.2%; mean 
FEV1, 67.5 ± 21.6%; mean MIP, 82 ± 58.4%; mean MEP, 78 ± 37.3%; mean heart rate at rest, 
75 ± 12.8 bpm; mean respiratory rate at rest, 19 ± 5.3 bpm; mean 6MWD, 478 ± 82 m; mean 
SpO2 at rest was 98 ± 0.8%; mean fall in SpO2, 4 ± 6 points. When the study population was 
divided according to the 400-m walk distance cut-off value, the heart rate immediately 
before the test was significant lower in those participants who walked less than 400 m (p = 
0.0043), just like the value of Borg scale (p = 0.0036); according to the presence of saturation 
≥ 4, heart rate at the end of the test was significantly higher in those participants who were 
showing desaturation (p = 0.0170); MEP (p = 0.0282) and 6MWD (p = 0.0291) were signifi-
cantly lower, and MIP showed a tendency towards being smaller (p = 0.0504). FVC < normal 
inferior limit was significantly associated with the group with desaturation (p = 0.0274).
Conclusion: Compared to 6MWD, desaturation was better suited to find the patients with the 
most compromised indexes in respiratory function tests.
© 2014 Sociedade Brasileira de Reumatologia. Published by Elsevier Editora Ltda. 
All rights reserved.
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Avaliação do comprometimento respiratório em pacientes com lúpus 
eritematoso sistêmico com o teste de caminhada de seis minutos
Palavras-chave:
Lúpus eritematoso sistêmico (LES)
Teste de caminhada de seis 
minutos
Saturação de oxigênio
Teste de função respiratória
Questionários
r e s u m o
Objetivo: Avaliar pacientes com LES estável, sem comprometimento respiratório evidente, 
por meio do TC6M.
Casuística e métodos: Foram recrutados 45 pacientes com LES estável. Foi utilizado o protoco-
lo ATS/ERS para TC6M, tendo sido escolhidos dois parâmetros com pontos de corte.
Resultados: Quarenta e dois dos pacientes eram mulheres. A média de idade foi 39 ± 11,4 anos; 
a duração média da doença, 121 ± 93,1 meses; valor médio de MRC 2 ± 0; CVF média 85,9 ± 
34,2%; VEF1 médio 67,5 ± 21,6%; PIM média 82 ± 58,4%; PEM média 78 ± 37,3%; frequência car-
díaca média em repouso 75 ± 12,8 bpm; frequência respiratória média em repouso 19 ± 5,3 
bpm; Distância média no TC6M 478 ± 82 m; SpO2 média em repouso 98 ± 0,8%; queda média 
em SpO2 4 ± 6 pontos. Quando a população em estudo foi dividida de acordo com o valor de 
corte de 400 m de distância caminhada, a frequência cardíaca imediatamente antes do tes-
te foi significativamente menor naqueles participantes que caminharam menos de 400 m 
(p = 0,0043), da mesma forma que o valor da escala de Borg (p = 0,0036). De acordo com a pre-
sença de saturação ≥ 4, a frequência cardíaca ao final do teste estava significativamente mais 
elevada naqueles participantes exibindo dessaturação (p = 0,0170); PEM (p = 0,0282) e TC6M 
(p = 0,0291) estavam significativamente menores e PIM revelou uma tendência para dimi-
nuir (p = 0,0504). CVF < limite inferior do normal foi achado significativamente associado 
com o grupo com dessaturação (p = 0,0274).
Conclusão: Comparado com TC6M, a dessaturação foi o indicador mais apropriado para lo-
calizar os pacientes com os índices mais comprometidos nos testes de função respiratória.
© 2014 Sociedade Brasileira de Reumatologia. Publicado por Elsevier Editora Ltda. 
Todos os direitos reservados.
Introduction
Systemic lupus erythematosus (SLE) is a progressive autoim-
mune disease of unknown etiology and a broad spectrum of 
clinical manifestations, that has a chronic course with peri-
ods of exacerbation and remission. According to American 
studies, the disease most frequently affects young women 
(9-10:1), with its prevalence ranging from 14 to 50/100.000 in-
habitants.1 A study involving Brazilian population observed 
a higher incidence in Caucasian patients2 and also in young 
women.3 In pulmonary manifestations, we have, by frequen-
cy, pleural involvement (pleural effusion, pleuritis). However, 
there may be vascular manifestations (pulmonary hyperten-
sion, alveolar hemorrhage), interstitial disease (interstitial 
pneumonia with possible progression to pulmonary fibrosis), 
neurological involvement (phrenic neuropathy and diaphrag-
matic paralysis), among other problems.4,5
The activation of the endothelial cells and the immuno-
logical deregulation, which leads to the production of many 
different autoantibodies, are the central pathological distur-
bances of the disease.5
The endothelial cells produce substances that control vas-
cular tone and activate the immune and coagulation systems 
which, in their turn, have the same endothelial cells as tar-
gets of the inflammation generated by the immune processes 
and the coagulation cascade. Vascular injury is probably the 
primary site of lesion in lupus pathogenesis.5 The activation 
and damage of the endothelial cells of the immune system 
are capable of explaining the involvement of the renal, central 
nervous, cardiovascular and respiratory systems in patients 
with SLE.6
Apart from serositis, no other pulmonary or respiratory in-
volvement appears in the list of diagnostic criteria proposed 
by the American College of Rheumatology (ACR).7 The diagno-
sis of SLE is not simple and requires the fulfillment of a mini-
mum number of criteria from a set developed by the ACR.8 
Various respiratory manifestations of SLE can provoke 
acute respiratory symptoms such as pleural thickening, pleu-
ral effusion and alveolar hemorrhage; however, some may be 
insidious and difficult to diagnose, such as interstitial lung 
disease or vascular disease, which are often silent for quite 
a long time.
Early diagnosis of respiratory involvement in patients 
with lupus is fundamental because it allows the therapeutic 
management established in the earliest stages of the disease, 
which can prevent the progression to a more dramatic func-
tional impairment. Therefore, it is essential to actively search 
for symptoms and to perform tests – preferably little or mini-
mally invasive – which indicate involvement in early disease. 
Thus, 6MWT is a submaximal exercise test that has already 
been validated in the evaluation of several lung diseases.9-13 
This test is easy to be performed, low cost and has a good cor-
relation with other more sophisticated tests such as the diffu-
sion test for carbon monoxide (DLCO) or cardiorespiratory.11,14
This study aimed to evaluate a patient group with stable 
SLE, without overt respiratory compromise, by six-minute 
walk test (6MWT), a self-paced and submaximal exercise test, 
in order to investigate the possibility of an unnoticed respira-
tory involvement.
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Methods
This was a cross-sectional study that enrolled stable SLE pa-
tients, diagnosed according to the updated and revised Amer-
ican College of Rheumatology (ACR) criteria,7 who attended 
the SLE outpatient clinic of the Teaching Hospital of the Uni-
versity of Campinas, between November 2007 and August 
2009. 
All patients were evaluated in order to check if there was 
presence of any respiratory symptom. The patients were clini-
cally stable – during the prior three months – using one or 
a combination of the following drugs: hydroxychloroquine, 
chloroquine, prednisone, azathioprine, and/or mycopheno-
late mofetil. None of them had recently changed their ther-
apeuthic regimen. Six months before the study, all patients 
were radiographically evaluated by a radiologist and, if it had 
been noticed the presence of pleural thickening or pleural 
abnormalities suggestive of interstitial involvement or in-
creased cardiac area in some of these patients, they would 
not have been included in the study.
Patients would not be considered eligible for the 6MWT 
if they had a recent chest X-Ray showing any abnormality, 
hemoglobin concentration below normal values, complaints 
that could interfere with the walk, if the oxygen saturation 
(SpO2) levels in rest were under 90% on ambient air, or the 
pulse signal on a pulse oximeter was inadequate due to Rayn-
aud’s phenomenon. Aiming to ensure an accurate assess-
ment of SpO2, the respiratory therapist checked if the pulse 
oximeter showed an acceptable pulse signal and if the oxim-
eter light was green and pulsing in synchrony with the heart 
rate before beginning all tests. 
The study was approved by the Research Ethics Committee 
of the Faculty of Medical Sciences of the University of Campi-
nas, and an informed consent was signed by each patient. 
The protocol used for the 6MWT was designed to ensure an 
accurate assessment of the walking distance and the oxygen 
desaturation, as proposed by the American Thoracic Society.8 
All patients were tested under standardized conditions by the 
same technician (ML). Baseline blood pressure and heart rate 
were measured and SpO2 was determined with a Nonin
® pulse 
oximeter (finger probe) (Nonin Medical, Inc; MN, USA). The 
walking course had 30 m of length. The patients walked on 
a level surface and were gently encouraged periodically. As-
sessment of dyspnea by the Borg index was performed at the 
beginning and at end of the test. SpO2 was measured at rest 
and immediately after the end of the 6-minute period, and 
the patients were carefully observed to avoid dangerously ex-
ceeding their exercise limits. 
For the purpose of data analysis, desaturation was defined 
as a decrease in SpO2 of 4 points or more (Δsat = resting satu-
ration – saturation immediately after the 6-minute period), 
in comparison with the initial values. Maximal distance was 
defined as the maximal achieved walking distance on room 
air 6MWT. 
Spirometric maneuvers were performed as recommended 
by Brazilian guidelines,15 and the curves for forced vital capac-
ity (FVC) and slow vital capacity (VC) were performed using a 
flow spirometer (microQuark model; COSMED Srl, Rome, Ita-
ly). The measured values were compared with those predicted 
for age, sex and height for each patient, and the inferior limit 
of the normal value for FVC was used to diagnose the reduc-
tion in FVC.16 
British MRC (Medical Research Council) questionnaire 
modified and translated to Portuguese was used to assess the 
degree of shortness of breath (0=o shortness of breath, except 
with strenuous exercise; 1=troubled by shortness of breath 
when hurrying or walking up a slight hill; 2=walks slower 
than people of the same age due to shortness of breath; need 
to stop for catch their breath when walking at their own pace; 
3=stops to breath after walking for approximately 100 m or 
after a few minutes; 4=show themselves with an excessive 
shortness of breath; breathless when dressing or undress-
ing).17 
The static maximum inspiratory pressure (MIP) and maxi-
mum expiratory pressure (MEP) were determined using a 
digital manuvacuometer (MVD30-Globalmed). The maneu-
vers were performed as recommended in ATS/ERS statement 
about respiratory muscle testing18, and the normal values 
were expressed as percentage of expected values predicted 
for Brazilians.19
The quantitative variables measured in these groups were 
submitted to the Anderson-Darling test to define their dis-
tribution. Variables with normal distribution were analyzed 
using the Student t test. Variables identified as not having a 
normal distribution were studied with the Wilcoxon test. The 
categorical data were compared using chi-square test or Fish-
er’s exact test when necessary. The statistical software used 
was SAS, version 8®. Differences were considered significant 
in the face of a p-value < 0.05. 
Results 
There were forty-five consecutive patients enrolled who 
agreed to participate in the study and fulfilled the inclusion 
criteria. There were 42 women with 39 ± 11.4 years, in total. 
None of the patients were smokers. The duration of the dis-
ease was 121 ± 93.1 months in the occasion. The character-
istics of the patients and their functional measurements are 
detailed in Table 1. 
The 6MWD was 478 ± 82 m and the SpO2 at rest was 98 ± 
0.8%. The fall in SpO2 at the end of the 6MWT was 4 ± 6 points. 
The spirometric evaluation showed FVC of 85.9 ± 34.2 (% of 
predicted value) and 21 patients with FVC below the limit of 
normality. The MIP was 82 ± 58.4 and MEP was 78 ± 37.3 (% of 
predicted value). 
For the purpose of data analysis, two main variables were 
defined and used to separate the study population in groups: 
a fall in saturation (Δsat) ≥ 4% and walking distance < 400 m. 
Considering the cut-off value of 400 m of walking distance,  no 
differences were found between the groups concerning age, 
disease duration, height, MIP, MEP, FVC, FEV1, FEV1/FVC, initial 
SpO2, Δsat, increase in heart rate, initial respiratory rate, in-
crease in respiratory rate, and increase in the Borg scale value. 
In addition, no association was found for the groups regarding 
sex, MRC value and the finding of a FVC inferior to the low 
limit of predicted value. The heart rate obtained immediately 
before the test was significantly smaller in those participants 
who walked less than 400 m (p = 0.004) when considering the 
195R E V  B R A S  R E U M A T O L .  2 0 1 4 ; 5 4 ( 3 ) : 1 9 2 – 1 9 9
Borg scale value (p = 0.004). The distance walked by the pa-
tients in the two groups was also significantly different (p < 
0.001): the value in the group ≥ 400 m was 505.3 ± 53.7 m; and 
in the group < 400 m was 350.8 ± 70.4 m (Table 2). 
When the population studied was divided in two groups, 
according to the presence of desaturation ≥ 4 by the end of the 
6MWT, no differences were found between the groups con-
cerning age, disease duration, height, FEV1/FVC, initial SpO2, 
initial heart rate, initial respiratory rate, increase in respira-
tory rate, initial value and increase in Borg scale. The heart 
rate at the end of the test was significantly higher in those 
participants who showed desaturation (p = 0.017). MEP was 
significantly lower in the group with desaturation (p = 0.028) 
and MIP as well, but it did not reach significance (p = 0.050). 
The distance walked by the patients in the two groups was 
also significantly different (p = 0.029): the value in the group 
with desaturation was 443.1 ± 94.6 m and in the group with-
out desaturation was 497 ± 68.5 m. The ΔSat was also signifi-
cantly different in the two groups: the value in the group with 
desaturation was 11.6 ± 4.6 points; and in the one without 
desaturation, the fall was of 0.5 ± 0.9 points. The finding of a 
FVC below the limit of the normal expected value was signifi-
cantly associated with the group with desaturation (p = 0.027) 
(Table 2). 
Discussion 
One finding that seems quite relevant in this study is that, 
within a population of SLE patients without relevant respira-
tory symptoms, the 6MWT can give useful information about 
respiratory compromise, especially if there is a reduction in 
SpO2 by the end of the test. It was considered a reduction equal 
to or greater than 4 points as significant, based on the findings 
by Prefaut et al., who validated this cut-off value in a study of 
exercise-induced hypoxemia during maximal exercise tests in 
athletes.20 This 4% fall was defined as accounted for potential 
inaccuracy of oximetry plus the effects of metabolic acidosis 
on the hemoglobin saturation curve (a right shift).9 
Subjects in this study with ΔSat ≥ 4% showed a significant 
reduction in walking distance (443 m versus 497 m, p = 0.029), 
although both values were way above the accepted inferior 
limit for 6MWD. Furthermore, these patients, when compared 
to those who did not desaturate had a higher heart rate at the 
end of the 6MWT (p = 0.017), lower MEP (p=0.028), lower MIP 
(p = 0.050) and a spirometry restrictive defect (FVC below the 
lower limit of predicted value, p = 0.027, with a normal FEV1/
FVC ratio).
Conversely, those who walked less than 400 m showed no 
significant differences regarding initial saturation or ΔSat ≥ 
4%. In addition, there were no significant differences between 
the groups with 6MWD < 400 m and MWD ≥ 400 m in spiro-
metric values, heart rate, static pressures or severity of dys-
pnea, either. 
These findings suggest the hypothesis that desaturation 
during the 6MWT may be a useful tool to evaluate SLE pa-
tients without respiratory symptoms – perhaps more sensi-
tive than the 6MWD.
The 6MWT is a standardized submaximal test of exercise 
capacity that is self-paced, simple, reproducible and inexpen-
sive. The measured variables are distance walked in 6 min-
utes (6MWD), symptoms and SpO2 at rest and at the end of 
the test.8 Because of its safety profile, physician attendance is 
not required, but a health professional, such as physiothera-
pist or a nurse, with clinical experience should supervise the 
patient during the test.
Age, sex, height, weight and ethnicity are important de-
terminants of an individual’s 6MWD. In general, men walk 
further than women; and the distance walked declines with 
increasing age.21 Equations are available to predict expected 
normal values of 6MWD, with some variation in the expected 
distances.21,22 A walking distance of less than 350 m has pre-
dictive value of increased mortality in a number of cardio-
pulmonary disorders, such as COPD, interstitial lung disease, 
pulmonary arterial hypertension, cystic fibrosis, congestive 
heart failure.10,11,14,22-24
Although the 6MWD is a sensitive measurement of walk-
ing ability for patients with moderate to severe disease, it is 
likely that its sensitivity in patients with better preserved 
exercise tolerance may not be so good. A ceiling effect was 
reported in patients with pulmonary arterial hypertension 
whose 6MWD is greater than 450 m, and this observation may 
be true for patients with other conditions.25
From the studies mentioned above, it can be seen that the 
cut-off value for the walking distance is not well established; 
apparently, it is between 350 m and 450 m.
In this study, only 8 patients walked less than 400 m, with 
median value of 367.5 m and mean value of 350.8 ± 70 m. 
For the groups separated by the walking distance, the only 
statistically significant differences were initial heart rate 
(slower for those who walked less) and degree of dyspnea in 
Borg scale (smaller for those who walked less). There were no 
significant differences for these variables at the end of the 
6MWT. It is hard to have an explanation for these findings, 
perhaps because of the small number of patients in one of 
the groups.
Table 1 – Study population characteristics and functional 
measurements (n = 45)
Variables Mean±SD Median  
(Min–Max)
Age (years) 39±11.4 39 (17-70)
Height (cm) 161±7.5 162 (145-179)
Duration of disease (months) 121±93.1 96 (12-373)
MRC questionnaire 2±0.5 2 (0-4)
FVC (% of predicted value) 85.9±34.2 81(31.6-247.7)
FEV1 (% of predicted value) 67.5±21.6 62.3 (30.4-113)
MIP (% of predicted value) 82±58.4 73(13-316)
MEP (% of predicted value) 78±37.3 75 (30-163)
Heart rate (bpm) 75±12.8 70 (57-99)
Respiratory rate (cpm) 19±5.3 18 (12-32)
SpO2 (%) 98±0.8 98 (94-99)
6MWD (m) 478±82 500 (180-600)
Δ SpO2(%) 4±6 1 (0-22)
Mean ± SD, mean ± standard deviation; Median (Min-Max), Median 
(minimum and maximum); MRC, Medical Research Council; FVC, 
Forced Capacity Value; FEV1, Forced Expired Volume in one second; 
MIP, Maximal Inspiratory Pressure; MEP, Maximal Expiratory 
Pressure; 6MWD, Six minute walk distance; cpm, cycles per minute; 































Table 2 – Comparison of functional variables and 6MWT parameters between the groups separated by distance and desaturation (n = 45)
6MWD Δ Sat
≥ 400 m (n=37) < 400 m (n= 8) p value With desaturation (fall in 




Mean ± SD Median 
(Min-Max)
Mean ± SD Median 
(Min-Max)
Mean ± SD Median 
(Min-Max)
Mean ± SD Median 
(Min-Max)
Age (years) 37.7±10.9 39 (17-62) 43.1±13.3 40.5(26-70) 0.307 38.9±9.2 38.5(17-51) 38.5±12.6 39(18-70) 0.914
Duration of disease (months) 118.7±98.5 84 (12-373) 129±67.2 126(24-240) 0.502 117±95.8 90(12-312) 122.5±93.2 120(12-373) 0.830
Height (cm) 160.7±8.0 160 (145-179) 163.4±4.1 163(157-169) 0.185 158.9±5.5 160(150-169) 162.4±8.2 163(145-179) 0.091
MIP * 83.5±61.6 73 (29-316) 73.5±42.8 65(13-137) 0.835 61±33 53.5(13-137) 93.1±66.3 84(30-316) 0.050
MEP * 78.9±37.1 75 (31-163) 76.3±40.4 71(30-123) 0.867 63.9±35.4 56.5(30-150) 86.5±36.4 81(32-163) 0.028
FVC * 85.7±35.9 80.4 (31.6-247.7) 87±26.4 89.7(53-127.3) 0.523 70.1±27.9 68.2(31.6-127.6) 94.7±34.5 93(53.4-247.7) 0.015
FEV1* 68.5±22.8 67.1 (30.4-113) 62.6±13.9 58.5(47.5-83.6) 0.352 57.5±18 55.8(30.4-91.3) 73±21.7 74.7(39.8-113) 0.015
FEV1/FVC 0.7±0.2 0.7 (0.39-0.99) 0.7±0.2 0.6(0.42-0.89) 0.355 0.7±0.1 0.7(0.49-0.94) 0.7±0.2 0.7(0.39-0.99) 0.231
Heart rate (bpm) 76.8±12.9 73 (57-99) 64±4.9 64(57-70) 0.004 76±15.8 69.5(57-99) 73.7±11.1 70(57-96) 0.952
Δ HR (bpm) 24.3±13.7 19 (4-60) 23.9±12.8 18(12-49) 0.917 29.4±12.2 28(15-51) 21.3±13.3 17(4-60) 0.017
Respiratory rate (cpm) 19.2±5.2 18 (12-32) 19±6.0 18(12-32) 0.856 21.4±6.3 20(12-32) 17.9±4.2 18(12-28) 0.080
Δ RR (cpm) 9±4.8 8 (0-20) 8.1±4.2 8(4-16) 0.610 10.6±5.1 10(3-20) 7.9±4.2 8(0-16) 0.080
Initial SpO2 % 98.1±0.8 98 (94-99) 97.9±0.8 98(96-99) 0.369 97.8±1.2 98(94-99) 98.2±0.5 98(97-99) 0.139
Δ SpO2 (in % points) 3.7±5.4 1 (0-16) 8±7.8 8(0-22) 0.127 11.6±4.6 12(4-22) 0.5±0.9 0(0-3) 0.000
Initial Borg 8.5±1.7 8 (6-13) 6.8±1.0 6.5(6-9) 0.003 7.8±1.4 8(6-10) 8.4±1.9 8(6-13) 0.396
Δ Borg 4.3±2.7 4 (0-10) 5.5±3.2 5.5(1-10) 0.330 5.4±3.1 5.5(1-10) 4±2.4 4(0-9) 0.132
6MWD (m) 505.3±53.7 510 (401-600) 350.8±70.4 367.5(180-397) 0.000 443.1±94.6 450(180-600) 497±68.5 512(360-600) 0.029
Mean ± SD, mean ± standard deviation; Median (Min-Max), Median (minimum and maximum); 6MWD, 6 minutes walked distance; Δ Sat, Final SpO2 – Initial SpO2; MIP, Maximal inspiratory pressure; 
MEP, Maximal expiratory pressure; FVC, Forced Capacity Value; FEV1, Forced Expired Volume in one second; HR, Heart rate; Δ HR, Final HR – Initial HR; cpm, cycles per minute; Δ RR, Final RR – Initial 
RR; Δ Borg, Final Borg – Initial Borg. 
Differences were considered significant with a p < 0.05.
aValues expressed as % of predicted value.
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The relation between walking distance and mortality is 
not seen in patients suffering from untreated pulmonary ar-
terial hypertension, in whom desaturation during the 6MWT 
was a better predictor of mortality than walking distance: for 
every percent decrease in SpO2 there was a 26% increase in 
the risk of death.12
The desaturation during 6MWT has demonstrated its val-
ue as an index of severity of disease and prognostic factor. 
Lama et al. showed that, in patients with interstitial pulmo-
nary fibrosis without resting hypoxemia, desaturation up to 
88% at any point during the 6MWT was associated to an in-
creased hazard of death; however,  no associations between 
6MWD and survival were observed.26 
In this study, FVC values below the lower limit of normal-
ity, simultaneously reduced FEV1 and normal FEV1/FVC in-
dexes, indicating the presence of a restrictive defect, were 
significantly more frequent among patients who showed de-
saturation. In addition, patients with desaturation had signifi-
cantly lower MEPs and showed a trend towards significantly 
lower MIPs. The 6MWD was not able to detect the patients 
who had reductions in FVC, and not even the ones with re-
duced expiratory pressures. In this study, desaturation was 
associated with lower 6MWD, although the mean walking 
distance in the group that showed desaturation was much 
greater than 350 m.
In our patients, an association between the presence of de-
saturation (Δsat ≥ 4%) with the values of MIP (p = 0.050) and 
MEP (p = 0.028) was observed, suggesting that some impair-
ment of respiratory muscles, not only the diaphragm, was 
present.
The presence of unexplained dyspnea, especially in the 
supine position, small lung volumes on chest radiographs, 
dysfunction and elevation of the diaphragm and pulmonary 
function tests displaying patterns of restrictive disease in the 
absence of parenchymal involvement prompt the diagnosis of 
shrinking lung syndrome.
Some authors found that the ability of the diaphragm to 
generate pressure is impaired in patients with the shrink-
ing lung syndrome;27 however, other authors28 were unable 
to show a reduced diaphragmatic strength in a cohort of 12 
patients.
In a comparison to the 6MWD, desaturation revealed it-
self as  better suited to find patients with the most impaired 
indexes in respiratory function tests. A previous published 
study, carried out by our group, showed that desaturation 
during a 6MWT provides additional information regarding 
severity of disease in patients with scleroderma presenting 
pulmonary manifestations.13 
Inter-test variation is high in cases of oxygen desatura-
tion. This fact implies that therapeutic decisions should not 
be based on a single measurement of exertional desaturation 
recorded on a 6MWT. This inter-test variation is expressed by 
the finding of different values of SpO2 at the end of various 
tests performed by the same patient.
In the study by Eaton et al., the value of hemoglobin de-
saturation upon pulse oximetry was found to be non-repro-
ducible, with unacceptable measurement variation. However, 
instead of using the hemoglobin desaturation as a categori-
cal variable, they computed the values of desaturation in two 
6MWTs.29 We believe that the important information here is 
the occurrence of desaturation per se, a fact that is not ob-
served in normal subjects.21 We surely expect the value of de-
saturation to vary because of different homeostatic situations 
at different moments in individuals with pulmonary diseases 
and in whom gas exchange abnormalities are probably pres-
ent.
Except for the involvement of the pleura, the most com-
mon pulmonary manifestation of SLE, all other pulmonary 
manifestations are infrequent, and many of them may cause 
decrease oxygenation during exercise, by different patho-
genic mechanisms. Those less common respiratory disorders 
in patients with SLE include: interstitial lung disease, acute 
lupus pneumonitis, diffuse alveolar hemorrhage, pulmonary 
arterial hypertension, thromboembolic disease, acute revers-
ible hypoxemia and shrinking lung syndrome. It is worth re-
minding that the prevalence of respiratory symptoms and 
signs in patients with SLE vary depending on several factors, 
most importantly the methods used for diagnosing respira-
tory tract compromise.
In athletes, the exercise-induced arterial hypoxemia is de-
fined as a reduction in the arterial O2 pressure (PaO2) by more 
than 1kPa and/or hemoglobin O2 saturation (SaO2) below 95%, 
both determined by blood gas analysis. Desaturation is con-
sistently found during maximal rowing ergometer and is most 
pronounced at the end of an exercise bout.30 Exercise-induced 
hypoxemia is explained by the interplay of many different fac-
tors. Alveolar PO2 must be maintained at a high level, so ven-
tilation becomes a critical issue. A widening of the PAO2-PaO2 
difference frequently occurs, indicating that diffusion limita-
tion or a ventilation-perfusion mismatch or shunt may be in-
fluencing the transport of oxygen from the alveoli to the pul-
monary capillaries. Cardiac output increases greatly, leading to 
a fast transit time of red cells in the lungs and further limiting 
O2 uptake. It is well known that a post-exercise reduction in 
pulmonary diffusion capacity really occurs, and this suggests 
damage to the alveolar-capillary membrane.31 All these factors 
have been proposed to be involved in exercise- induced hypox-
emia, but the six-minute walk test is a submaximal exercise. 
Disease states may facilitate the occurrence of desaturation by 
all these mechanisms.
Vascular injury with endothelial cell activation and damage 
play a central role in the pathogenesis of SLE.5 The vascular en-
dothelial growth factor (VEGF) is the main mediator of angio-
genesis, and increased levels of VEGF were found in serum from 
patients with rheumatoid arthritis, dermatomyositis/polymyo-
sitis, sclerodermapolymyositis, scleroderma complicated by 
interstitial lung disease,32 and SLE.33 The mitogen is connected 
to vascular hypertrophy, inflammation, tissue remodeling, ex-
tracellular matrix synthesis and fibrosis.34 Increased levels of 
endothelin-1, a potent vasoconstrictor, were observed in many 
collagen-vascular diseases including SLE. 
The combination of inflammatory vascular lesion, slightly 
elevated arterial pulmonary pressures and initial fibrotic inter-
stitial disease impaired function of diaphragm with exercise 
stress, although submaximal, may explain the occurrence of 
desaturation during the 6MWT in SLE patients.
Only the follow-up of these patients will be able to clari-
fy the relevance of this desaturation during 6MWT; however, 
given the available data from studies that used other diseases, 
such as idiopathic pulmonary fibrosis and pulmonary arte-
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rial hypertension, associated with a poor prognosis, a close 
monitoring of the patients with SLE who presented desatura-
tion during the 6MWT is advisable. A recently published study 
assesses the association between quality of life and distance 
walked during the 6MWT in Brazilian premenopausal patients 
with SLE and compared with a healthy control group. The au-
thors of this study concluded that patients with SLE walked a 
shorter distance during the 6MWT, which was associated with 
poorer quality of life.35 In addition to that, the finding of desatu-
ration justifies the indication of a more thorough cardiorespi-
ratory evaluation using echocardiogram, CT scans, measure-
ments of diffusion capacity and total lung capacity. 
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